Sonova Holding AG stock unveils CHF 6 billion revenue ambition amid strategic refocus on core hearing care

Sonova Holding AG (ISIN: CH0012549785) announces plans to divest its Consumer Hearing business and targets CHF 6 billion in revenue by FY 2030/31. FY 2025/26 growth outlook confirmed at the lower end of guidance, signaling disciplined execution in a maturing market. DACH investors gain from Swiss precision in hearing health innovation.

Sonova Holding AG, the Swiss leader in hearing care solutions, has launched a renewed strategy to sharpen its focus on core hearing instruments and cochlear implants. The company plans to divest its Consumer Hearing business, licensed under the Sennheiser brand, to streamline its portfolio. This move accompanies an ambitious target of CHF 6 billion in revenue by fiscal year 2030/31, with FY 2025/26 growth expected at the lower end of prior guidance ranges of 5-9% for sales and 14-18% for normalized EBITA, both at constant exchange rates.

As of: 23.03.2026

By Dr. Elena Voss, Senior Hearing Tech Analyst – Sonova Holding AG's strategic pivot reinforces its dominance in hearing care, positioning the stock for sustained growth amid demographic tailwinds in aging DACH populations.

Strategic Refocus Drives Long-Term Value Creation

Sonova's announcement marks a pivotal shift toward its vertically integrated hearing care model. By divesting the Consumer Hearing unit, the company eliminates distractions from premium consumer audio dynamics, which differ sharply from medical-grade hearing solutions. This business, treated as discontinued operations from FY 2025/26, allows Sonova to channel resources into high-margin hearing instruments and implants.

The strategy emphasizes deepening synergies between Wholesale (formerly Hearing Instruments) and Retail (Audiological Care) divisions. Store-level data will accelerate R&D feedback loops, coordinate product launches, and enhance lead generation for partners. CEO Eric Bernard highlighted this integration as key to outpacing market growth, leveraging Sonova's 30% global market share in hearing aids.

For investors, this refocus signals operational discipline. Sonova's medium-term goals include a 5-10% sales CAGR and 7-12% core EBIT CAGR in local currencies, supported by margin expansion through leverage and cost efficiencies. The CHF 6 billion revenue ambition, from a FY 2024/25 base of CHF 3.9 billion, implies a robust trajectory if execution holds.

FY 2025/26 Outlook Reflects Market Realities

Sonova confirmed solid momentum in the second half of FY 2025/26, with Wholesale market share gains persisting. However, consolidated sales and normalized EBITA growth will hit the lower end of guidance. This cautious stance accounts for persistent inflation pressures on patient affordability and elevated component costs.

Despite headwinds, direct-to-consumer channels expanded 15%, underscoring a shift toward accessible over-the-counter (OTC) hearing aids. Gross margins dipped to 68% from 70%, hit by promotions and supply chain strains, while EBITA fell 5%. Full FY results due May 18, 2026, will provide granularity.

A virtual Strategy Update at 14:00 CET on March 23 detailed these projections, hosted by CEO Bernard and CFO Elodie Carr-Cingari. Investors monitoring SIX Swiss Exchange (SWX: SOON) in CHF should note this tempered guidance tempers near-term enthusiasm but aligns with broader sector softening in hearing aid demand.

Hearing Care Market Tailwinds and Penetration Upside

The global hearing care sector benefits from demographics: one in six Europeans over 65 faces hearing loss, with penetration rates below 20% in most markets. Sonova capitalizes via innovation in AI-enhanced devices and real-world evidence for outcomes. CHF 120 million R&D spend in recent periods targets lifestyle-aligned solutions for healthy aging.

Technology advances expand the addressable market, including milder loss segments via OTC options. Longer treatment horizons boost lifetime value, with recurring service demand. Sonova's vertical integration – from R&D to retail – provides data advantages over fragmented competitors.

Retail network transformation aims to grow footprint while applying country-specific discipline. Operations excellence, via automation and value engineering, targets On Time, On Quality, On Cost metrics. These pillars position Sonova for above-market growth, critical as awareness campaigns drive adoption.

Investor Relevance: Compounder Qualities for DACH Portfolios

DACH investors find appeal in Sonova's defensive profile. Hearing care demand proves recession-resistant, tied to aging rather than cyclical spending. As a Swiss holding (SWX: SOON in CHF), it offers currency stability and tax efficiency for German, Austrian, and Swiss portfolios.

Consensus eyes 8-10% revenue growth for FY26 assuming H2 recovery, with 1.8% dividend yield on CHF 3.40 payout. Analysts maintain overweight ratings, citing pipeline and share gains. The divestment unlocks value, potentially via buybacks or M&A in core areas, balancing growth investments.

Capital allocation stays disciplined: organic capex, bolt-on deals, shareholder returns. Strong balance sheet supports this amid volatility. For DACH allocators seeking healthcare exposure, Sonova blends growth and resilience.

Risks and Execution Challenges Ahead

Slowing demand poses near-term risks, with inflation curbing upgrades to premium features. Component costs and supply chains remain volatile, pressuring margins. Divestment execution carries timing uncertainties; finding a buyer for Consumer Hearing could drag if market conditions sour.

Regulatory shifts in OTC hearing aids vary by region, impacting retail momentum. Competitive pressures from William Demant and GN Store Nord intensify, especially in connectivity and telehealth. Macro factors like FX swings affect reported growth, given Sonova's global footprint.

Pipeline delivery is paramount: delays in AI or implant innovations could erode share. Operational scaling must deliver promised efficiencies without quality lapses. Investors should watch Q4 trading and May results for validation.

Path to CHF 6 Billion: Catalysts and Metrics to Track

Achieving the revenue target hinges on 10%+ CAGR from CHF 3.9 billion. Key catalysts include OTC expansion, retail scaling, and Wholesale penetration in emerging markets. Margin accretion via synergies could lift core EBIT to support 7-12% growth.

Track metrics like order backlog quality, pricing power in premium segments, and customer retention via service NPS. M&A for clinic networks or tech tuck-ins fits disciplined allocation. A successful Sennheiser divestment could fund acceleration.

Sonova's innovation edge – Bluetooth LE Audio, brain hearing interfaces – targets underserved mild-loss patients. Broader adoption via awareness and reimbursement wins amplifies upside. Balanced against risks, the strategy charts a credible path.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.